New Partnership Aims to Improve Insulin Access
Indonesia and Russia are working together to boost domestic insulin production for patients.
Updated on Oct. 25, 2026 in Diabetes
Live Poll
Should the government prioritize domestic manufacturing to reduce the country's reliance on imported medicine?
Indonesia and Russia are pursuing a pharmaceutical partnership to bolster domestic insulin production and improve patient access. The collaboration focuses on technology transfers and regulatory cooperation to help integrate Russian manufacturing expertise into Indonesia's healthcare supply chain.
Why it matters
Reducing reliance on imported medication is a strategic priority for Indonesia to ensure stable, long-term access to critical diabetes treatments for its population. This partnership aims to stabilize supply chains by localizing manufacturing processes.
Official regulatory data shows that 5 or 6 Russian pharmaceutical companies have submitted product registration applications to the Indonesian Food and Drug Authority (BPOM). It remains unknown when these manufacturing partnerships will culminate in the commercial availability of new insulin options.
The players
BPOM
Indonesia's regulatory agency responsible for ensuring the safety and quality of food and drug products.
State Institute of Drugs and Good Practices
A Russian federal organization that oversees pharmaceutical manufacturing standards and GMP compliance.
Eurasian Academy of Good Practices
An educational institution providing technical training for pharmaceutical inspectors and industry professionals.
The details
The initiative hinges on Good Manufacturing Practice (GMP) alignment, which ensures that facilities producing sensitive biologic drugs like insulin meet rigorous international standards for safety and purity. Through the exchange of virtual reality training simulations and mock inspections, the two nations are harmonizing their oversight processes. By aligning these regulatory standards, Indonesia aims to streamline the approval of incoming manufacturers while maintaining patient safety oversight.
Timeline
2016: Russia's State Institute of Drugs and Good Practices began conducting international GMP inspections.
2021: BPOM and the State Institute of Drugs and Good Practices launched initial cooperation initiatives.
May 2026: BPOM conducted a GMP inspection at an insulin manufacturing facility in Russia.
October 24, 2026: Indonesian and Russian officials met in Jakarta to discuss technology transfers.
Health Landscape
This collaboration follows the global trend of the State Institute of Drugs and Good Practices' international GMP inspection program, which has spanned 75 countries since 2016. It marks a shift toward regional pharmaceutical independence through shared regulatory infrastructure.
This regulatory progress aims to stabilize the long-term availability of essential insulin products within the Indonesian healthcare system. If you rely on insulin, it is worth discussing potential changes to your medication supply or future availability with your primary care physician.
The takeaway
The move toward localizing insulin production is part of a broader push to make essential disease treatments more accessible. Always consult your doctor before making any adjustments to your medication regimen or if you have concerns regarding your current treatment plan.
Further reading
Learn more about the latest innovations and management strategies in Diabetes.
Source note: This article includes information reported by Antara News.
Live Poll
Should the government prioritize domestic manufacturing to reduce the country's reliance on imported medicine?
